Disease-Modifying Agents for Multiple Sclerosis
- 1 January 2008
- journal article
- review article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 68 (17), 2445-2468
- https://doi.org/10.2165/0003495-200868170-00004
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease of the CNS. Currently, six medications are approved for immunmodulatory and immunosuppressive treatment of the relapsing disease course and...This publication has 264 references indexed in Scilit:
- Progressive multifocal leukoencephalopathy in rheumatic diseases: Evolving clinical and pathologic patterns of diseaseArthritis & Rheumatism, 2007
- Immune control by endocannabinoids — New mechanisms of neuroprotection?Journal of Neuroimmunology, 2007
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosisTrends in Molecular Medicine, 2006
- Autologous haematopoietic-stem-cell transplantation for multiple sclerosisThe Lancet Neurology, 2005
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002
- Neurodegeneration: a failure of neuroregeneration?The Lancet, 2001
- Axonal Transection in the Lesions of Multiple SclerosisThe New England Journal of Medicine, 1998
- Management of Multiple SclerosisThe New England Journal of Medicine, 1997
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995